Cytogenetic abnormalities are used to define prognostic subgroups of acute myelogenous leukemia (AML) with respect to achieving complete remission (CR) and remaining disease free. These prognostic groups for obtaining CR were based on an induction regimen mainly using standard dose cytosine arabinoside (Ara-C) + daunorubicin (DNR). We have reviewed our experience with 122 adult patients with de novo non-M3 AML who were treated with high-dose (HD) Ara-C 3 g/m 2 given over 3 h every 12 h for a total of eight doses followed by DNR 60 mg/m 2 daily for 2 days. CR was obtained in 80% while 16% had refractory disease and 4% died of sepsis during hypoplasia. CR rate for favorable, intermediate and unfavorable cytogenetic groups were 87%, 79% and 62%, respectively (P = 0.32). High white blood cell count, age, FAB subtype and LDH levels did not adversely affect CR rate. Eighty-five percent of patients achieved CR with one course of treatment and 87% of complete responders were able to receive post remission therapy. Highdose Ara-C/DNR appears to offer an excellent chance of achieving remission for patients with AML including those with poor risk cytogenetics, without an increase in early toxic deaths.
Introduction
Cytosine arabinoside (Ara-C) and anthracyclines have been the mainstay of induction chemotherapy for the treatment of acute myelogenous leukemia (AML) for the past three decades. Between 40 and 70% of adult patients with de novo AML achieve a morphologic hematologic remission, following one induction with standard dose Ara-C (100-200 mg/m 2 c.i. × 7 days). However, 20-30% of these patients required a second cycle of chemotherapy to achieve remission resulting in a prolonged period of pancytopenia, with its attendant drawback of high infectious complications and prolonged hospital stay. [1] [2] [3] [4] [5] [6] [7] When high-dose (HD) Ara-C is used alone or in combination with an anthracycline, mitoxantrone, amsacrine or Lasparaginase for patients with relapsed AML the CR rates range from 42 to 71%. [8] [9] [10] [11] Patients who fail to attain a remission with standard dose Ara-C or who have persistent disease at day 6 are often able to achieve a remission with HD Ara-C by overcoming the resistance that leukemic cells may have to standard dose Ara-C. 12 The proposed mechanism of its effectiveness is related to increasing Ara-C entry into cells and saturating deaminating enzyme capacity, leading to higher levels of intracellular 1-␤-D-arabinofuranylcytosinetriphosphate with enhanced inhibition of DNA synthesis. 13, 14 Correspondence Because HD Ara-C appears to be effective in patients whose leukemia has become resistant to standard-dose Ara-C therapy and has improved disease-free survival when used as consolidation treatment, [8] [9] [10] [11] 15, 16 we studied the efficacy and toxicity of HD Ara-C in combination with daunorubicin (DNR) for induction therapy in previously untreated de novo AML. In addition we attempted to determine: (1) the number of patients who could achieve a CR in a single induction cycle; (2) the ability of patients to receive post remission consolidation or intensification therapy; and (3) whether intensive Ara-C dosing had an impact on previously described poor prognostic variables for successful induction therapy including: age, FAB type, LDH, elevated WBC at presentation, cytogenetics at diagnosis and residual leukemia 1 week following completion of treatment (day 13 marrow).
We initially reported the results of a pilot study of this regimen in 27 adult patients with de novo AML in which 81% achieved a CR. 17 We are now reporting on an analysis of 122 consecutively treated patients using this regimen and the impact of cytogenetics and other poor prognostic markers at diagnosis on the ability of this regimen to achieve a remission.
Materials and methods

Patients
We have reviewed the results of 122 consecutive adult patients with newly diagnosed de novo AML who were treated between April 1983 and September 1993 with HD Ara-C/DNR induction therapy at City of Hope National Medical Center. Informed consent was obtained from each patient according to institutional guidelines. Eligibility criteria included AML, FAB M0-M7 excluding M3, age Ͼ18 and Ͻ69 years (patients over the age of 60 were subsequently excluded from the study after the reported increased incidence of cerebellar toxicity in this age group). Patients were excluded if they had a known antecedent myelodysplasia or myeloproliferative syndrome.
The median age was 41 years with 13% being Ͻ25 years and 6% of patients у60 years. Sixteen percent of patients had FAB M0 + M1, 36% FAB M2, 30% FAB M4 + M5, 2% had M4eo and 1% FAB M6.
Treatment
Ara-C 3 g/m 2 was administered via continuous infusion over 3 h every 12 h for eight doses on days 1 to 4 of therapy followed by DNR 60 mg/m 2 on days 5 and 6. A bone marrow aspiration and biopsy was performed on day 13 following initiation of chemotherapy. Patients thought to have residual leukemia (defined by cellularity Ͼ25% or 10% leukemic cells), received four additional doses of HD Ara-C and one dose of DNR at the doses described above. A marrow examination was repeated 2 weeks later to document remission. If residual or recurrent leukemia was found on that sample, the patient could receive a second 6-day regimen identical to the initial induction therapy. Toxicity grade was based on NCI Common Toxicity Criteria.
Supportive care
Patients were housed in conventional hospital rooms without HEPA filters. Steroid eye drops were administered prophylactically for 10 days after the beginning of therapy to prevent Ara-C-induced conjunctivitis. All patients had indwelling central venous catheters. Patients received parental nutrition if unable to eat, and broad-spectrum antibiotics were used for the first febrile episode. No gastrointestinal decontamination was used and no patient received hematopoietic growth factors.
Cytogenetics
Cytogenetic studies on pretreatment bone marrow or unstimulated blood samples were performed using standard G-banding with trypsin-Giemsa staining. Karyotypes were interpreted using International System for Human Cytogenetic Nomenclature (ISCN), 1995. Karyotypes were considered normal diploid if no clonal abnormalities were detected in a minimum of 20 metaphases examined and if two independent cell-processing methods were used.
Patients were assigned to a cytogenetic category based on the probability of obtaining a CR as reported in the MRC AML 10 Trial. 18 Patients with t(8;21), inv(16)/t(16;16), were assigned to the favorable group. The intermediate prognostic subgroup included patients with normal cytogenetics, +8 (excluding those with t(15;17)), 11q23 abnormalities, 7q− as the sole abnormality, and patients with miscellaneous single abnormalities. The unfavorable group included patients with the following abnormalities: у5 abnormalities (complex karyotype), t(6;9), inv(3)(q21q26.2) or t(3;3) and −7. Patients with t(6;9) were included in the unfavorable group based on reported poor response to therapy.
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The criteria for complete remission were marrow cellularity of Ͼ20% with maturation of all cell lines and Ͻ5% blasts and no Auer rods, peripheral blood counts with neutrophils Ͼ1500/l and platelets Ͼ100 000/l and no extramedullary disease for 4 weeks or present at the start of consolidation therapy. 22 
Statistical methods
Univariate logistic regression was used to identify potential prognostic factors that may be significantly associated with CR. Exact methods were used to accommodate CR rates of 100% in several categories. All variables with a value Ͻ0.20 univariately were included as candidate variables for the multivariate logistic regression analysis. Risk ratios and 95% confidence intervals (CI) were calculated for each factor. The prognostic factors examined for their impact on successful induction were age, FAB, LDH, WBC, cytogenetics and residual leukemia at day 13. Significance was established at a two-sided alpha level of 0.05.
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Results
One hundred and twenty-two consecutive adult patients diagnosed with AML were treated with HD Ara-C/DNR induction chemotherapy. Ninety-seven patients achieved CR (80%), 20 had persistent disease (16%) and five died of sepsis (4%) during hypoplasia. The median time to achieve CR was 33 days for patients receiving only the initial induction and 52 days for those patients requiring treatment based on day 13 marrow.
Thirty-three patients (27%) had not achieved marrow aplasia by day 13. Based on the results of that marrow, 25 patients received additional treatment with 14 achieving CR. Eight patients did not receive chemotherapy midcycle due to active infection or organ toxicity; seven of these patients recovered normal hematopoiesis by day 28-30. Seven patients who had marrow aplasia on day 13 had evidence of persistent leukemia upon recovery of peripheral blood counts; following a second full course of induction four achieved CR. The CR rate was 80% (97/122) with 82% of patients requiring only a single treatment (eight doses of Ara-C + two DNR) to reach remission. Additional therapy with either a half course at day 13 (14 patients) or a full reinduction (four patients) benefited 15% of patients.
Prognostic factors Cytogenetics effect on CR:
Evaluable cytogenetics were available for 103 of 122 (84%) patients. CR rates for groups of patients with specific cytogenetic abnormalities and for those in whom no abnormalities were detected are listed in Table 1 .
Fifteen patients had favorable cytogenetics and 87% achieved a complete remission. One patient with inv(16) failed to achieve a remission and one patient with t(8;21) died of sepsis during marrow aplasia without evidence of residual leukemia.
The CR rate for 73 patients with intermediate cytogenetic risk class was 79%. The majority (70%) of this group was comprised of patients with normal karyotypes. Of the remaining 22 patients, two of the three patients with +8 and two of three patients with 11q23 abnormalities achieved CR. Both patients with 7q− achieved a remission and eight of 14 patients with miscellaneous abnormalities achieved a CR.
Complete remissions were obtained in eight of 13 patients (62%) with unfavorable cytogenetics including all six patients with complex karyotypes.
Sixteen percent of patients had inadequate metaphases for analysis; the remission rate (85%) in this group was comparable to that of the favorable group with known cytogenetics.
Other prognostic factors effect on CR:
The impact of other clinical variables that have previously been reported to be predictive of attaining CR are listed in Table 2 . Logistic regression analyses were performed to determine which prognostic factors were predictive of CR. Only residual leukemia at day 13 was predictive for an adverse outcome (P = 0.008). 
Toxicity
Five patients died before marrow recovery due to septic complications (4%). Nine patients (7%) developed у grade 2 cerebellar toxicity; their ages ranged from 21 to 54 years. In our study there was no statistical link demonstrated between patients who developed renal insufficiency and cerebellar toxicity. Other common toxicities у grade 2 included: (1) fever (95%) (patients were not premedicated with corticosteroids); (2) liver function abnormalities (68%); (3) GI dysfunction emesis, diarrhea or mucositis occurred in 46%; and (4) a macular papular erythematous rash in 48 patients (33%). The time to neutrophils Ͼ500 and Ͼ1000 in patients not requiring day 13 treatment was 23 days (range 14-34) and 25 days (17-Leukemia 40), respectively, and for patients requiring day 13 treatment it was 33 days (range 20-53) and 35 days (21-56), respectively. The time to platelets Ͼ20 000 in patients not requiring day 13 treatment was 20 days (11-34) and for patients requiring day 13 treatment it was 32 days (18-76).
Ability to receive further consolidation treatment
Eighty-eight percent (85/97) of complete responders went on to receive consolidation treatment either with post-remission chemotherapy alone (40) or followed by autologous bone marrow transplant (19) , or allogeneic bone marrow transplant (26) . Twelve percent (12/97) of patients did not receive post-remission therapy for the following reasons: (1) five had persistent infections with fungi or bacteria; (2) one refused further treatment; (3) three had persistent hepatitis either of viral origin or secondary to Ara-C; (4) one relapsed and (5) two for ongoing prior medical conditions. All of these patients subsequently relapsed.
Discussion
The ideal induction chemotherapy regimen for adult AML should provide a rapid attainment of CR with one course of induction therapy in a high percentage of patients. This objective should be accomplished with low toxicity to non-hematopoietic systems allowing patients to proceed expeditiously to post-remission therapy without which nearly all patients will succumb to recurrent leukemia. Ideally, the regimen should be able to overcome identifiable poor risk factors, offer an improved CR rate, and ultimately CR duration in combination with intensive post-remission therapy.
In our study, 80% of patients achieved CR, treatmentrelated mortality was low at 4% and 16% of patients had resistant disease. Eighty-two percent of patients achieved CR with only one course of chemotherapy. In the CALGB study, which used standard dose Ara-C (200 mg/m 2 /day × 7 days) and DNR, the CR rate for patients less than 60 years old was 71%; however 33% of patients required a second course of chemotherapy to achieve CR which contributed to a higher mortality rate (14%). 16 The Australian Leukemia (ALSG) study reported equivalent CR rates (71% vs 74%) in their comparison of HD Ara-C vs standard Ara-C/DNR/etoposide, with more patients achieving CR with a single cycle of HD Ara-C vs standard dose Ara-C (60% vs 48%, P = 0.04). In the standard dose arm, 39% of patients received two or more courses. 25 In the other large trial from SWOG comparing standard dose Ara-C with high dose (2 g/m 2 q 12 h × 12 doses) the CR rates in both arms were lower (54% or 51%) with no advantage for earlier CR rates with HD Ara-C (40% or 41%, respectively), presumably due to the higher mortality rates (16% vs 8%) associated with HD Ara-C given for 6 days compared to standard Ara-C. 26 These results suggest patients receiving HD Ara-C induction chemotherapy are more likely to achieve CR with a single course of therapy, and the achievement of a CR with a single course may also be a factor favoring long-term outcome. 27 Acquired cytogenetic aberrations have been identified in Ͼ50% of patients with newly diagnosed AML. The impact of these karyotypic abnormalities on both the ability to achieve and sustain remission was first identified in the mid 1980s. Based on 290 patients with de novo AML treated with standard-dose Ara-C/DNR, the Fourth International Working Group on Chromosomes in Leukemia discerned that patients with t(8;21) or inv (16) consistently achieved CR in Ͼ80% of patients (favorable risk) while patients with either loss or gain of whole chromosomes or −5q or −7q had less than 50% chance of remission (poor risk). Patients without detectable abnormalities (ie normal), 11q abnormalities or t(15;17) had intermediate remission rates of 60-75%. 28 Revisions of this prognostic scoring system have been proposed by various cooperative groups (MRC, 18 CALGB, 29 and SWOG 30 ). In the recent MRC 10 trial which used two cycles of daunorubicin, cytarabine and thioguanine (DAT) or daunorubicin, cytarabine and etoposide (ADE) chemotherapy for induction, the overall CR rate at the end of two full cycles was 82%; however only 57% were in CR at the end of one cycle with an additional 22% reaching remission after the second cycle. 31 In this study, 90% of patients with favorable cytogenetics attained CR while patients with normal karyotype had an 88% remission rate. The intermediate cytogenetic risk group with aberrations including del (7q), 11q23 abnormalities, +8, and +21 had CR range of 75-87%. 31 However, even after two cycles of induction chemotherapy, patients with adverse cytogenetics (complex, −7, -5/del(5q) abn(3q)) had a CR range of 42-67%.
In the SWOG Intergroup Trial which used standard-dose Ara-C/DNR induction and compared three high intensity consolidation treatment the overall CR rate was 71% with remission rates ranging from 84% for favorable (t(15;17), inv16 and t(8;21)), 76% for intermediate and 56% for unfavorable which included del(7q) and 11q abnormalities. 30 Using MRC criteria, our study CR rates were 87% for the core binding factor abnormalities 79% for intermediate and 62% for unfavorable group. For patients with five or more abnormalities, 100% of patients achieved CR. These data suggest that HD Ara-C might improve CR rates for poor risk groups, especially those with complex abnormalities. Randomized studies comparing high-and standard-dose cytarabine for induction therapy in newly diagnosed AML patients show equivalent CR rates, but no data are available on the effect of karyotype on CR rates. 25, 26 The German AML Cooperative Group compared two courses of standard-dose cytarabine, daunorubicin and 6-thioguanine (TAD) to one course of TAD followed by high-dose cytarabine and mitoxantrone (HAM) for induction therapy for AML. The CR rate was similar for both groups (65% vs 71%). However, patients with unfavorable karyotype who received high-dose Ara-C had an improved CR rate (P = 0.011). 32 This is the first randomized study to demonstrate an improved CR rate for a subgroup of AML who are treated with high-dose Ara-C induction therapy.
Updated results of ALSG study 33 with the median duration of follow-up of 5.7 years for surviving patients reported equivalent CR rates in their comparison of HD Ara-C vs standard Ara-C/DNR/etoposide but the estimated median remission duration was 46 months with HD Ara-C and 12 months with standard Ara-C (P = 0.007). The relapse free survival was 48% vs 25% and the median duration of survival after CR was 38 months with HD Ara-C vs 22 months with standard Ara-C. The SWOG trial 26 also indicates that patients receiving HD Ara-C induction had improved disease-free survivals while the CALGB 16 comparison of HD Ara-C vs intermediate-and standard-dose Ara-C indicate that HD Ara-C consolidation also improves disease-free survival. At the present time it remains unclear when HD Ara-C should be given. The ALSG 33, 34 conducted a phase I/II study to determine the safety and efficacy of the combination of idarubicin, cytarabine and etoposide for induction and consolidation and dose intensification of cytarabine in this setting. They demonstrated that cytarabine dose can be escalated safely in combination with idarubicin and etoposide in both induction and consolidation. Whether its use offers long-term benefits compared to standard regimens remains to be answered in future randomized studies.
The regimen detailed in this study provided a relatively safe dose intensive schedule that achieved high CR rates usually with a single cycle of chemotherapy. The regimen-related mortality was 4% and the high-dose schedule appeared to overcome some poor risk karyotypic features, such as complex karyotype, high LDH and WBC at presentation. Importantly, the majority of patients were able to begin consolidation chemotherapy without a long delay. While this study can not address disease-free survival due to the heterogeneity of the consolidation regimens, HD Ara-C + anthracycline offers a strong foundation for patients to receive a post-induction dose-intensive approach.
